Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00139620
Status:
COMPLETED
Last Update Posted:
2018-02-08
First Post:
2005-08-25
Brief Title:
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors With Adequate and Moderately Impaired Hepatic Function
Sponsor:
OSI Pharmaceuticals
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib Tarceva OSI-774 in Cancer Patients With Advanced Solid Tumors With Adequate and Moderately Impaired Hepatic Function
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open-label 2-arm study comparing erlotinib exposure in cancer patients with adequate hepatic function versus cancer patients with moderate hepatic impairment All patients will receive a single 150 mg dose of erlotinib on Day 1 followed by 96 hours of plasma sampling for PK and protein binding studies Patients may then enter the maintenance phase of the study and continue to receive erlotinib until disease progression or unacceptable toxicity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-002363-59 | EUDRACT_NUMBER | None | None |